Clinical Trials for Peripheral T-Cell Lymphoma (PTCL)
Peripheral T-cell lymphoma (PTCL) is a group of rare, aggressive non-Hodgkin lymphomas arising from mature T-cells. Clinical trials offer access to novel targeted therapies, antibody-drug conjugates, epigenetic drugs, and combination regimens.
Live from our database
TrialCompass currently tracks 123 curated clinical trials for PTCL
PTCL includes several distinct subtypes — PTCL-NOS, AITL/TFH, ALCL (ALK-positive and ALK-negative), and others. TrialCompass lets you filter trials by your specific subtype.
What types of PTCL trials are available?
Trials are grouped by where you are in your treatment journey.
Newly diagnosed
Frontline trials evaluate new combinations and targeted agents added to (or replacing) standard first-line therapy.
Relapsed / refractory
Trials for disease that returned or did not respond, including novel targeted therapies, antibody-drug conjugates, and cellular therapies.
Maintenance / remission
Studies of consolidation or maintenance strategies aimed at keeping the disease from returning after a response.
How to use TrialCompass
- 1Browse PTCL trials and use the sidebar filters to narrow by treatment stage, phase, or U.S. state.
- 2Ask the AI Assistant a plain-language question — it searches only trials curated by our hematology specialist.
- 3Generate a letter to bring trials of interest to your oncology team for eligibility review.
Related resources
For completeness, you can also search the U.S. federal registry at ClinicalTrials.gov. TrialCompass curates a physician-selected subset so patients don't have to sift through hundreds of listings.